Are primary tumors suitable for biomarker-guided treatment of metastatic urothelial cancer?

Transl Androl Urol. 2024 Aug 31;13(8):1341-1345. doi: 10.21037/tau-24-112. Epub 2024 Aug 26.

Authors

Mathijs P Scholtes¹, Geert J L H van Leenders², Debbie G J Robbrecht³, Joost L Boormans¹, Tahlita C M Zuiverloon¹

Affiliations

¹ Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
² Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.
³ Department of Medical Oncology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

No abstract available

Keywords: Metastatic urothelial carcinoma (mUC); biomarkers; metastatic evolution; molecular subtypes.

Publication types

Editorial
Comment